Central Provident Fund (Medisave Account Withdrawals) (Amendment No. 3) Regulations 2024

No. S 696

Central Provident Fund Act 1953

Central Provident Fund
(Medisave Account Withdrawals)
(Amendment No. 3) Regulations 2024

In exercise of the powers conferred by section 77(1)(j) of the Central Provident Fund Act 1953, the Minister for Manpower, after consulting with the Central Provident Fund Board, makes the following Regulations:

Citation and commencement

1. These Regulations are the Central Provident Fund (Medisave Account Withdrawals) (Amendment No. 3) Regulations 2024 and come into operation on 6 September 2024.

Amendment of regulation 2

2. In the Central Provident Fund (Medisave Account Withdrawals) Regulations (Rg 17) (called in these Regulations the principal Regulations), in regulation 2 —

(a)

in paragraph (1), replace the definition of “approved remote consultation” with —

“ “approved remote consultation”, in relation to any Sixth Schedule treatment, means the Sixth Schedule treatment, including any consultation for that Sixth Schedule treatment, received by remote provision approved under section 11B of the Healthcare Services Act 2020 as a service delivery mode for that Sixth Schedule treatment;”;

(b)

in paragraph (1), in the definition of “MIC@Home treatment”, delete paragraph (b);

(c)

in paragraph (1), in the definition of “MIC@Home treatment”, in paragraph (c), delete “or (b)”;

(d)

in paragraph (1), after the definition of “Singapore Gamma Knife Centre”, insert —

“ “Sixth Schedule treatment” means each type of treatment specified in the first column of the Sixth Schedule;”; and

(e)

after paragraph (4), insert —

“(5) For the purposes of this Part, unless the context otherwise requires —

(a)

every reference to any type of treatment specified in the first column of the Sixth Schedule (whether by a specific reference or by a collective term, such as medical treatment or an approved treatment package, which includes that type of treatment) includes approved remote consultation in relation to that type of treatment received on an out‑patient basis in the circumstances specified in the second column of the Sixth Schedule for that type of treatment; and

(b)

each type of treatment specified in the first column of the Sixth Schedule is subject to the same limit on withdrawal prescribed in the applicable provision specified in the third column of the Sixth Schedule for that type of treatment whether or not it is received as approved remote consultation.”.

Amendment of regulation 3

3. In the principal Regulations, in regulation 3(1)(b), delete “, or by way of approved remote consultation,”.

Amendment of regulation 9A

4. In the principal Regulations, in regulation 9A(1), delete sub‑paragraph (aa).

Amendment of regulation 14

5. In the principal Regulations, in regulation 14(1), replace “, or at home or by way of approved remote consultation” with “or at home”.

Amendment of regulation 24

6. In the principal Regulations, in regulation 24(1) —

(a)	in sub-paragraph (f)(ii), delete “or by way of approved remote consultation”; and
(b)	in sub-paragraph (i), delete “, or by way of approved remote consultation,”.

Amendment of regulation 26

7. In the principal Regulations, in regulation 26(b), delete “or by way of approved remote consultation”.

New Sixth Schedule

8. In the principal Regulations, after the Fifth Schedule, insert —

“SIXTH SCHEDULE

Regulation 2(1) and (5)

First column

Second column

Third column

Treatment

Circumstances for
receipt of treatment by
approved remote consultation

Applicable provision
on withdrawal limit

1.	Approved cancer drug administered for the treatment of neoplasms

Received from an approved medical practitioner as a patient of an approved hospital or approved clinic

Regulation 13(7A), read with item 13 or 14 of the First Schedule, as applicable

2.	Approved chronic illness treatment

Received on or after 1 July 2023 from an approved medical practitioner as a patient of an approved CIT medical institution

Regulations 14(1) and 14C

3.	Approved rehabilitation treatment

Received from an approved day rehabilitation centre

Regulation 10

4.	Approved screening

Received from an approved medical practitioner as a patient of an approved clinic, approved hospital or approved screening centre

Regulations 14B and 14C

5.	Approved vaccination

Received from an approved medical practitioner as a patient of an approved clinic, approved hospital, approved community hospital or approved CIT medical institution

Regulations 14A and 14C

6.	Blood transfusions and desferrioxamine for the medical treatment of thalassaemia

Received from an approved medical practitioner as a patient of an approved hospital

Regulation 13(3), read with item 6 of the First Schedule

7.	Bone marrow transplant

Received from an approved medical practitioner as a patient of an approved Third Schedule treatment provider

Regulation 13(3A), read with item 1 of the Third Schedule

8.	Cancer drug treatment (excluding the cost of any cancer drug administered), cancer scan or diagnostic test

Received from an approved medical practitioner as a patient of an approved hospital or approved clinic

Regulation 13(7A), read with item 12 or 12A of the First Schedule, as applicable

9.	Home palliative care (other than any approved vaccination)

Received on or after 1 July 2023 from an approved home palliative care provider

Regulation 9A

10.	Hyperbaric oxygen therapy

Received from an approved medical practitioner as a patient of an approved hospital

Regulation 13(3), read with item 7 of the First Schedule

11.	Intravenous antibiotic infusion

Received from an approved medical practitioner as a patient of an approved Third Schedule treatment provider

Regulation 13(3A), read with item 2 of the Third Schedule

12.	Medical treatment for conception as part of a treatment cycle

Received from an approved medical practitioner as a patient of an approved hospital or approved clinic

Regulation 18

13.	MIC@Home treatment (excluding ambulance service), including such treatment provided as part of qualifying combined treatment

Received on or after 1 April 2024 from an approved medical practitioner as a patient under the MIC@Home programme

Regulation 12A or 13B, as applicable

14.	Pre‑delivery medical treatment

Received from an approved medical practitioner as a patient of an approved hospital

Regulation 16(11A) and (11B)

15.	Radiotherapy treatment

Received from an approved medical practitioner as a patient of an approved hospital or approved clinic

Regulation 13(3), read with item 1 of the First Schedule

”.

[G.N. Nos. S 224/2007; S 527/2007; S 731/2007; S 149/2008; S 456/2008; S 682/2008; S 86/2009; S 239/2009; S 523/2009; S 659/2009; S 88/2010; S 118/2010; S 289/2010; S 548/2010; S 367/2011; S 725/2011; S 107/2013; S 482/2013; S 623/2013; S 427/2014; S 872/2014; S 177/2015; S 625/2015; S 377/2016; S 530/2016; S 723/2016; S 340/2017; S 789/2017; S 145/2018; S 341/2018; S 730/2018; S 787/2018; S 397/2019; S 200/2020; S 389/2020; S 855/2020; S 899/2020; S 1089/2020; S 131/2021; S 157/2021; S 315/2021; S 3/2022; S 285/2022; S 716/2022; S 770/2022; S 466/2023; S 652/2023; S 773/2023; S 59/2024; S 558/2024]

Made on 4 September 2024.

NG CHEE KHERN

Permanent Secretary,
Ministry of Manpower,
Singapore.

[Plg&Pol/CPFPol/Legis/CPFSL/2024; AG/LEGIS/SL/36/2020/3]

(To be presented to Parliament under section 78(2) of the Central Provident Fund Act 1953).

Search within Legislation